Skip to main content
Kringle Pharma,Inc. logo

Kringle Pharma,Inc. — Investor Relations & Filings

Ticker · 4884 ISIN · JP3270790003 T Manufacturing
Open in API
Filings indexed 53 across all filing types
Latest filing 2026-05-20 Share Issue/Capital Cha…
Country JP Japan
Listing T 4884

About Kringle Pharma,Inc.

https://www.kringle-pharma.com/en/

Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable and rare diseases. The company's core technology is based on recombinant human Hepatocyte Growth Factor (HGF), an endogenous protein with tissue-protective, regenerative, and repairing functions. Kringle Pharma has established a platform to manufacture pharmaceutical-grade HGF protein and is conducting clinical trials for several indications. Key development programs target conditions including acute spinal cord injury, vocal fold scarring, and Amyotrophic Lateral Sclerosis (ALS).

Recent filings

Filing Released Lang Actions
第三者割当により発行された第16回新株予約権（行使価額修正条項付）の大量行使に関するお知らせ
Share Issue/Capital Change Classification · 95% confidence The document is a corporate notice regarding the large exercise of third-party allocated stock warrants (第16回新株予約権) and the resulting share allotments. It provides detailed figures on warrants exercised, shares issued, and outstanding warrants—typical content for a share issuance and capital structure change announcement. This fits the definition for Share Issue/Capital Change (SHA), not a financial report or other regulatory filing.
2026-05-20 Japanese
2026年９月期 第２四半期決算説明会 質疑応答について
Call Transcript Classification · 87% confidence The document is titled “2026年9月期 第2四半期決算説明会 質疑応答” and contains a question‐and‐answer transcript from the company’s second-quarter earnings presentation. It does not include formal financial statements or an earnings summary but is clearly the verbatim (with minor edits) Q&A from an investor earnings event. This matches the definition of a conference call/presentation transcript rather than a standalone earnings release or interim report.
2026-05-18 Japanese
2026年9月期 第2四半期決算説明会資料
Regulatory Filings
2026-05-14 Japanese
確認書
Regulatory Filings Classification · 78% confidence The document is a confirmation letter (確認書) under Japan’s Financial Instruments and Exchange Act (Article 24-5), signed by the CEO and CFO asserting the proper preparation of the half-year report. It contains no substantive financial statements or analysis, only officer certification. Under the Certification Rule, this is a regulatory attestation and should be classified as a general Regulatory Filing (RNS), not as the actual interim report.
2026-05-11 Japanese
半期報告書－第25期(2025/10/01－2026/09/30)
Interim / Quarterly Report Classification · 98% confidence The document is titled “半期報告書” and covers the company’s mid-year period from 2025-10-01 to 2026-03-31, includes detailed financial statements, cash flows, management discussion and analysis for that six-month period. It is thus an interim (semiannual) report, matching the definition of “Interim / Quarterly Report” (IR). H1 2026
2026-05-11 Japanese
2026年９月期第２四半期決算短信〔日本基準〕（非連結）
Interim / Quarterly Report Classification · 90% confidence The document is titled “2026年9月期 第2四半期（中間期）決算短信〔日本基準〕（非連結）” and contains actual interim financial statements (balance sheet, income statement, cash flows), quantitative performance data for the half‐year period, management commentary, and full notes. It is not merely an earnings press release or an announcement of a report but a comprehensive interim report. This matches the definition for an Interim / Quarterly Report (IR). H1 2026
2026-05-11 Japanese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.